Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

632

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets

10 mg Dapagliflozin/1000 mg Metformin HCl extended-release

DRUG

Dapagliflozin tablets and Metformin HCl extended-release tablets

Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg

Trial Locations (35)

100020

Research Site, Beijing

100050

Research Site, Beijing

100076

Research Site, Beijing

102218

Research Site, Beijing

116001

Research Site, Dalian

124000

Research Site, Panjin

214400

Research Site, Jiangyin

215500

Research Site, Suzhou

226001

Research Site, Nantong

230012

Research Site, Hefei

236400

Research Site, Fuyang

261035

Research Site, Weifang

266200

Research Site, Qingdao

300134

Research Site, Tianjin

311899

Research Site, Zhuji

325000

Research Site, Wenzhou

325200

Research Site, Rui’an

330006

Research Site, Nanchang

362000

Research Site, Quanzhou

402260

Research Site, Chongqing

410005

Research Site, Changsha

430010

Research Site, Wuhan

450052

Research Site, Zhengzhou

459003

Research Site, Jiyuan

510180

Research Site, Guangzhou

510515

Research Site, Guangzhou

518101

Research Site, Shenzhen

550044

Research Site, Guiyang

562100

Research Site, Dingzhou

610072

Research Site, Chengdu

610500

Research Site, Yibin

650032

Research Site, Kunming

675000

Research Site, Chuxiong

Unknown

Research Site, Nanning

030001

Research Site, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY